23亿美元打水漂？辉瑞终止最后一项CD47明星实验

生物药大时代2025-07-01

单曲声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。6月30日，据外媒报道，辉瑞已经终止CD47 项目中maplirpacept（前身为TTI-622）与化疗药物来那度胺（lenalidomide）联合用于复发或难治性弥漫性大B细胞淋巴瘤患者的2期研究。发言人表示，终止该研究是由于“招募受阻，并非安全...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2548202840?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-01 10:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2548202840","market":"us","top_or_hot":-1,"title":"23亿美元打水漂？辉瑞终止最后一项CD47明星实验","media":"生物药大时代","content":"<div>\n<p>单曲声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。6月30日，据外媒报道，辉瑞已经终止CD47 项目中maplirpacept（前身为TTI-622）与化疗药物来那度胺（lenalidomide）联合用于复发或难治性弥漫性大B细胞淋巴瘤患者的2期研究。发言人表示，终止该研究是由于“招募受阻，并非安全...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103523a4c7db5f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>23亿美元打水漂？辉瑞终止最后一项CD47明星实验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n23亿美元打水漂？辉瑞终止最后一项CD47明星实验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-01 10:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103523a4c7db5f&s=b><strong>生物药大时代</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>单曲声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。6月30日，据外媒报道，辉瑞已经终止CD47 项目中maplirpacept（前身为TTI-622）与化疗药物来那度胺（lenalidomide）联合用于复发或难治性弥漫性大B细胞淋巴瘤患者的2期研究。发言人表示，终止该研究是由于“招募受阻，并非安全...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103523a4c7db5f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103523a4c7db5f&s=b","article_id":"2548202840","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701103523a4c7db5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2548202840","pubTimestamp":1751337151,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"6月30日，据外媒报道，辉瑞已经终止CD47 项目中maplirpacept 与化疗药物来那度胺联合用于复发或难治性弥漫性大B细胞淋巴瘤患者的2期研究。发言人表示，终止该研究是由于“招募受阻，并非安全或疗效翻车”。TTI-622是2021年辉瑞斥资22.6亿美元收购Trillium公司而获得的第2个CD47项目，另一个是TTI-621，此前辉瑞已经停止TTI-621的开发，这意味着辉瑞收购而来的两条CD47路线全部按下暂停键。TTI-621 和 TTI-622 结构CD47 曾经是新癌症药物的有前途的靶点。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BK4599":"减肥药","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4585":"ETF&股票定投概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4534":"瑞士信贷持仓","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4592":"伊斯兰概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4568":"美国抗疫概念","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4550":"红杉资本持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4588":"碎股","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0058720904.USD":"联博国际健康护理基金A","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4007":"制药","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","PFE":"辉瑞","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus"},"translate_title":"$2.3 billion wasted? Pfizer Terminates Last CD47 Star Trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"单曲声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。6月30日，据外媒报道，辉瑞已经终止CD47 项目中maplirpacept（前身为TTI-622）与化疗药物来那度胺（lenalidomide）联合用于复发或难治性弥漫性大B细胞淋巴瘤患者的2期研究。发言人表示，终止该研究是由于“招募受阻，并非安全或疗效翻车”。此外，公司仍在几种血液恶性肿瘤，如多发性骨髓瘤中测试该药。TTI-622是2021年辉瑞斥资22.6亿美元收购Trillium公司而获得的第2个CD47项目，另一个是TTI-621，此前辉瑞已经停止TTI-621的开发，这意味着辉瑞收购而来的两条CD47路线全部按下暂停键。CD47是细胞表面的“don’t eat me”信号，肿瘤通过它向巨噬细胞发送“我是自己人别吞我”的假象。maplirpacept采用SIRPα-IgG4 Fc融合蛋白设计，一边阻断CD47-SIRPα配对，一边通过IgG4弱Fc激活温和吞噬；更关键是工程化后对红细胞亲和性极低，理论上可避开贫血副作用 。正因这个差异化卖点，辉瑞才敢豪掷重金接盘。TTI-621 和 TTI-622 结构CD47 曾经是新癌症药物的有前途的靶点。但近期，国外CD47赛道哀鸿遍野：ALX Oncology的evorpacept先后在MDS、AML、胃癌等多项Ⅱ期失利，公司被迫裁员、砍管线；更早之前吉利德斩掉了57亿美金买来的magrolimabⅢ期项目，因安全事件被FDA叫停临床研究，随后治疗无效、安全性不足等问题持续发酵，在2023年，两项治疗血液瘤的临床研究暂停，再到2024年4月，吉利德宣布彻底放弃Magrolimab的6项实体瘤研究；另外，之前艾伯维与天境生物就CD47抗体Lemzoparlimab的合作协议，也随着艾伯维以“战略调整”原因退出，使天境生物重获CD47抗体的全球权益，得以继续探索Lemzoparlimab未来的开发机会。总结尽管前路艰难，CD47研发仍存希望，国内biotech新一代药物的设计逻辑正在颠覆传统路径，成为CD47的曙光。其中宜明昂科靶向CD47的IMM01（timdarpacept/替达派西普）则是最大的看点之一，主要针对骨髓增生异常综合征（MDS）、经典霍奇金淋巴瘤（cHL）和慢性粒单核细胞白血病（CMML）3个适应证。而康方生物的的AK117，作为一款不诱导红细胞凝集的CD47阻断抗体，在红细胞凝集试验中其在高达3000nM的浓度下也不诱导红细胞凝集（Hu5F9-G4在低至4.1nM的浓度下可诱导），在成药性上无疑是颇具希望的。除此之外，目前CD47靶点上，我国诸多药企在开发双抗路线，如信达布局了CD47/PD-L1双抗，康方布局了Claudin 18.2/CD47双抗，德升济医药布局了HER2/CD47双抗…有望在保证安全性的同时，保持一定的肿瘤杀伤效果。在吉利德、ALX等先行者的不断试错后，国内biotech的差异化路径或将重新定义这一靶点的未来。正如PD-1历经十年坎坷终成基石，CD47的“黎明前的黑暗”或许正是破晓的信号。参考资料：www.endpoints.news","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2548202840","isCrawlerRequest":true}